Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

Sabine Kayser , Robert K Hills, Marlise R Luskin, Andrew M Brunner, Christine Terré, Jörg Westermann, Kamal Menghrajani, Carole Shaw, Maria R Baer, Michelle A Elliott , Alexander E Perl Zdeněk Ráčil, Jiri Mayer, Pavel Zak, Tomas Szotkowski

. 2020 ; 105 (1) : 161-169.

Jazyk angličtina Země Itálie

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20016076

Grantová podpora
NV15-25809A MZ0 CEP - Centrální evidence projektů

Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation (allo-HCT) may improve survival if performed early during first complete remission. We report on a cohort of 178 patients with t(6;9)(p22;q34) within an international, multicenter collaboration. Median age was 46 years (range: 16-76), AML was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. Complete remission was achieved in 81% (n=144), including 14 patients who received high-dose cytarabine after initial induction failure. With a median follow up of 5.43 years, estimated overall survival at five years was 38% (95%CI: 31-47%). Allo-HCT was performed in 117 (66%) patients, including 89 in first complete remission. Allo-HCT in first complete remission was associated with higher 5-year relapse-free and overall survival as compared to consolidation chemotherapy: 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%) versus 7% (95%CI: 3-19%) and 23% (95%CI: 13-38%), respectively. For patients undergoing allo-HCT, there was no difference in overall survival rates at five years according to whether it was performed in first [53% (95%CI: 42-66%)], or second [58% (95%CI: 31-100%); n=10] complete remission or with active disease/relapse [54% (95%CI: 34-84%); n=18] (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclusion, outcomes of t(6;9)(p22;q34) AML are poor with chemotherapy, and can be substantially improved with allo-HCT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20016076
003      
CZ-PrNML
005      
20240624085050.0
007      
ta
008      
201014s2020 it f 000 0|eng||
009      
AR
024    0_
$a 10.3324/haematol.2018.208678 $2 DOI
035    __
$a (Pubmed)31004014
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Kayser, Sabine $u Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany
245    10
$a Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study / $c Sabine Kayser , Robert K Hills, Marlise R Luskin, Andrew M Brunner, Christine Terré, Jörg Westermann, Kamal Menghrajani, Carole Shaw, Maria R Baer, Michelle A Elliott , Alexander E Perl Zdeněk Ráčil, Jiri Mayer, Pavel Zak, Tomas Szotkowski
520    9_
$a Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation (allo-HCT) may improve survival if performed early during first complete remission. We report on a cohort of 178 patients with t(6;9)(p22;q34) within an international, multicenter collaboration. Median age was 46 years (range: 16-76), AML was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. Complete remission was achieved in 81% (n=144), including 14 patients who received high-dose cytarabine after initial induction failure. With a median follow up of 5.43 years, estimated overall survival at five years was 38% (95%CI: 31-47%). Allo-HCT was performed in 117 (66%) patients, including 89 in first complete remission. Allo-HCT in first complete remission was associated with higher 5-year relapse-free and overall survival as compared to consolidation chemotherapy: 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%) versus 7% (95%CI: 3-19%) and 23% (95%CI: 13-38%), respectively. For patients undergoing allo-HCT, there was no difference in overall survival rates at five years according to whether it was performed in first [53% (95%CI: 42-66%)], or second [58% (95%CI: 31-100%); n=10] complete remission or with active disease/relapse [54% (95%CI: 34-84%); n=18] (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclusion, outcomes of t(6;9)(p22;q34) AML are poor with chemotherapy, and can be substantially improved with allo-HCT.
650    17
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380 $2 czmesh
650    17
$a akutní myeloidní leukemie $x chirurgie $7 D015470 $2 czmesh
650    _7
$a allogeneické buňky $7 D000078422 $2 czmesh
650    _7
$a dospělí $7 D000328 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Hills, Robert K. $u Cardiff University School of Medicine, Cardiff, UK
700    1_
$a Luskin, Marlise R. $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
700    1_
$a Brunner, Andrew M. $u Massachusetts General Hospital, Boston, MA, USA
700    1_
$a Terré, Christine $u Laboratory of Hematology, André Mignot Hospital, Le Chesnay, France
700    1_
$a Westermann, Jörg $u Department of Hematology, Oncology and Tumor Immunology, Charité-University Medical Center, Campus Virchow Clinic, Berlin, Germany
700    1_
$a Menghrajani, Kamal $u Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
700    1_
$a Shaw, Carole $u Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
700    1_
$a Baer, Maria R. $u University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA
700    1_
$a Elliott, Michelle A. $u Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
700    1_
$a Perl, Alexander E. $u Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Ráčil, Zdeněk, $d 1974- $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic $7 mzk2006354038
700    1_
$a Mayer, Jiří, $d 1960- $7 nlk20000083651 $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Žák, Pavel, $d 1966- $7 mzk2006354145 $u 4 Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Szotkowski, Tomáš $7 xx0060568 $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
773    0_
$t Haematologica $x 0390-6078 $g Roč. 105, č. 1 (2020), s. 161-169 $w MED00001963
910    __
$a ABA008 $y 0 $z 0
990    __
$a 20201014160114 $b ABA008
991    __
$a 20240624085048 $b ABA008
999    __
$a kom $b bmc $g 1572611 $s 1106248
BAS    __
$a 3
BMC    __
$a 2020 $b 105 $c 1 $d 161-169 $x MED00001963 $i 0390-6078 $m Haematologica
GRA    __
$a NV15-25809A $p MZ0
LZP    __
$c NLK120 $d 20240621 $a 2020-grant

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace